Verastem, Inc.
Verastem, Inc. (2VSA.F) Stock Competitors & Peer Comparison
See (2VSA.F) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| 2VSA.F | €5.30 | -1.85% | 294M | -1.84 | -€2.91 | N/A |
| NOV.DE | €41.95 | +1.41% | 194.7B | 13.30 | €3.14 | +3.65% |
| VX1.DE | €396.85 | -2.80% | 101.9B | -120.62 | -€3.29 | N/A |
| DUL.DE | €227.20 | +0.00% | 27.3B | -31.91 | -€7.12 | N/A |
| 22UA.F | €91.35 | -4.79% | 22B | -28.64 | -€3.19 | N/A |
| BM8.DE | €61.96 | -1.71% | 11.8B | 88.51 | €0.70 | N/A |
| 0QF.F | €23.61 | -16.53% | 10.2B | -3.50 | -€7.56 | N/A |
| EX9.DE | €32.28 | +1.22% | 9.2B | 35.47 | €0.91 | N/A |
| MOR.DE | €67.25 | -0.66% | 2.5B | -12.16 | -€5.53 | N/A |
| BBZA.DE | €34.40 | -3.37% | 1.9B | -4.12 | -€8.35 | +5.47% |
Stock Comparison
2VSA.F vs NOV.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, NOV.DE has a market cap of 194.7B. Regarding current trading prices, 2VSA.F is priced at €5.30, while NOV.DE trades at €41.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas NOV.DE's P/E ratio is 13.30. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to NOV.DE's ROE of +0.81%. Regarding short-term risk, 2VSA.F is more volatile compared to NOV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check NOV.DE's competition here
2VSA.F vs VX1.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, VX1.DE has a market cap of 101.9B. Regarding current trading prices, 2VSA.F is priced at €5.30, while VX1.DE trades at €396.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas VX1.DE's P/E ratio is -120.62. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to VX1.DE's ROE of -0.06%. Regarding short-term risk, 2VSA.F is more volatile compared to VX1.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check VX1.DE's competition here
2VSA.F vs DUL.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, DUL.DE has a market cap of 27.3B. Regarding current trading prices, 2VSA.F is priced at €5.30, while DUL.DE trades at €227.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas DUL.DE's P/E ratio is -31.91. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to DUL.DE's ROE of +9.05%. Regarding short-term risk, 2VSA.F is more volatile compared to DUL.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check DUL.DE's competition here
2VSA.F vs 22UA.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 22UA.F has a market cap of 22B. Regarding current trading prices, 2VSA.F is priced at €5.30, while 22UA.F trades at €91.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 22UA.F's P/E ratio is -28.64. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 22UA.F's ROE of -0.04%. Regarding short-term risk, 2VSA.F is more volatile compared to 22UA.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 22UA.F's competition here
2VSA.F vs BM8.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, BM8.DE has a market cap of 11.8B. Regarding current trading prices, 2VSA.F is priced at €5.30, while BM8.DE trades at €61.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas BM8.DE's P/E ratio is 88.51. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to BM8.DE's ROE of +0.08%. Regarding short-term risk, 2VSA.F is more volatile compared to BM8.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check BM8.DE's competition here
2VSA.F vs 0QF.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 0QF.F has a market cap of 10.2B. Regarding current trading prices, 2VSA.F is priced at €5.30, while 0QF.F trades at €23.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 0QF.F's P/E ratio is -3.50. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 0QF.F's ROE of -0.30%. Regarding short-term risk, 2VSA.F is less volatile compared to 0QF.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check 0QF.F's competition here
2VSA.F vs EX9.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, EX9.DE has a market cap of 9.2B. Regarding current trading prices, 2VSA.F is priced at €5.30, while EX9.DE trades at €32.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas EX9.DE's P/E ratio is 35.47. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to EX9.DE's ROE of +0.24%. Regarding short-term risk, 2VSA.F is more volatile compared to EX9.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check EX9.DE's competition here
2VSA.F vs MOR.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, MOR.DE has a market cap of 2.5B. Regarding current trading prices, 2VSA.F is priced at €5.30, while MOR.DE trades at €67.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas MOR.DE's P/E ratio is -12.16. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to MOR.DE's ROE of +2.51%. Regarding short-term risk, 2VSA.F is more volatile compared to MOR.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check MOR.DE's competition here
2VSA.F vs BBZA.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, BBZA.DE has a market cap of 1.9B. Regarding current trading prices, 2VSA.F is priced at €5.30, while BBZA.DE trades at €34.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas BBZA.DE's P/E ratio is -4.12. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to BBZA.DE's ROE of -0.19%. Regarding short-term risk, 2VSA.F is more volatile compared to BBZA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check BBZA.DE's competition here
2VSA.F vs BIO3.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, BIO3.DE has a market cap of 1.4B. Regarding current trading prices, 2VSA.F is priced at €5.30, while BIO3.DE trades at €28.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas BIO3.DE's P/E ratio is -45.08. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to BIO3.DE's ROE of +0.05%. Regarding short-term risk, 2VSA.F is less volatile compared to BIO3.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check BIO3.DE's competition here
2VSA.F vs BIO.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, BIO.DE has a market cap of 1.4B. Regarding current trading prices, 2VSA.F is priced at €5.30, while BIO.DE trades at €42.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas BIO.DE's P/E ratio is -66.98. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to BIO.DE's ROE of +0.05%. Regarding short-term risk, 2VSA.F is more volatile compared to BIO.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check BIO.DE's competition here
2VSA.F vs IMU.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, IMU.DE has a market cap of 1.1B. Regarding current trading prices, 2VSA.F is priced at €5.30, while IMU.DE trades at €5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas IMU.DE's P/E ratio is -9.22. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to IMU.DE's ROE of -0.93%. Regarding short-term risk, 2VSA.F is more volatile compared to IMU.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check IMU.DE's competition here
2VSA.F vs 5CV.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 5CV.DE has a market cap of 1B. Regarding current trading prices, 2VSA.F is priced at €5.30, while 5CV.DE trades at €4.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 5CV.DE's P/E ratio is 5.81. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 5CV.DE's ROE of +0.30%. Regarding short-term risk, 2VSA.F is more volatile compared to 5CV.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 5CV.DE's competition here
2VSA.F vs 5CV.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 5CV.F has a market cap of 1B. Regarding current trading prices, 2VSA.F is priced at €5.30, while 5CV.F trades at €4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 5CV.F's P/E ratio is 5.80. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 5CV.F's ROE of +0.30%. Regarding short-term risk, 2VSA.F is more volatile compared to 5CV.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 5CV.F's competition here
2VSA.F vs NVV1.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, NVV1.F has a market cap of 910.6M. Regarding current trading prices, 2VSA.F is priced at €5.30, while NVV1.F trades at €5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas NVV1.F's P/E ratio is 2.36. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to NVV1.F's ROE of -1.16%. Regarding short-term risk, 2VSA.F is less volatile compared to NVV1.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check NVV1.F's competition here
2VSA.F vs GBY.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, GBY.DE has a market cap of 884.7M. Regarding current trading prices, 2VSA.F is priced at €5.30, while GBY.DE trades at €5.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas GBY.DE's P/E ratio is -4.38. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to GBY.DE's ROE of -2.75%. Regarding short-term risk, 2VSA.F is more volatile compared to GBY.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check GBY.DE's competition here
2VSA.F vs 2EM.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 2EM.DE has a market cap of 586M. Regarding current trading prices, 2VSA.F is priced at €5.30, while 2EM.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 2EM.DE's P/E ratio is 34.38. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 2EM.DE's ROE of +0.20%. Regarding short-term risk, 2VSA.F is more volatile compared to 2EM.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 2EM.DE's competition here
2VSA.F vs FYB.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, FYB.DE has a market cap of 467.2M. Regarding current trading prices, 2VSA.F is priced at €5.30, while FYB.DE trades at €26.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas FYB.DE's P/E ratio is -3.68. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to FYB.DE's ROE of -0.24%. Regarding short-term risk, 2VSA.F is less volatile compared to FYB.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check FYB.DE's competition here
2VSA.F vs HPHA.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, HPHA.DE has a market cap of 195.3M. Regarding current trading prices, 2VSA.F is priced at €5.30, while HPHA.DE trades at €4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas HPHA.DE's P/E ratio is -8.38. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to HPHA.DE's ROE of -0.63%. Regarding short-term risk, 2VSA.F is more volatile compared to HPHA.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check HPHA.DE's competition here
2VSA.F vs 88Q.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 88Q.DE has a market cap of 170.3M. Regarding current trading prices, 2VSA.F is priced at €5.30, while 88Q.DE trades at €11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 88Q.DE's P/E ratio is -9.91. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 88Q.DE's ROE of -0.95%. Regarding short-term risk, 2VSA.F is more volatile compared to 88Q.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 88Q.DE's competition here
2VSA.F vs VSC.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, VSC.DE has a market cap of 150.7M. Regarding current trading prices, 2VSA.F is priced at €5.30, while VSC.DE trades at €2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas VSC.DE's P/E ratio is -7.27. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to VSC.DE's ROE of -0.90%. Regarding short-term risk, 2VSA.F is more volatile compared to VSC.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check VSC.DE's competition here
2VSA.F vs IF0.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, IF0.DE has a market cap of 129.9M. Regarding current trading prices, 2VSA.F is priced at €5.30, while IF0.DE trades at €2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas IF0.DE's P/E ratio is -2.43. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to IF0.DE's ROE of -0.66%. Regarding short-term risk, 2VSA.F is more volatile compared to IF0.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check IF0.DE's competition here
2VSA.F vs 94E.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, 94E.F has a market cap of 74.2M. Regarding current trading prices, 2VSA.F is priced at €5.30, while 94E.F trades at €1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas 94E.F's P/E ratio is -1.79. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to 94E.F's ROE of -0.43%. Regarding short-term risk, 2VSA.F is more volatile compared to 94E.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check 94E.F's competition here
2VSA.F vs BNN.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, BNN.DE has a market cap of 47M. Regarding current trading prices, 2VSA.F is priced at €5.30, while BNN.DE trades at €2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas BNN.DE's P/E ratio is -3.47. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to BNN.DE's ROE of -1.24%. Regarding short-term risk, 2VSA.F is less volatile compared to BNN.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check BNN.DE's competition here
2VSA.F vs C6O.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, C6O.DE has a market cap of 13.2M. Regarding current trading prices, 2VSA.F is priced at €5.30, while C6O.DE trades at €0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas C6O.DE's P/E ratio is -0.05. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to C6O.DE's ROE of +1.21%. Regarding short-term risk, 2VSA.F is less volatile compared to C6O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check C6O.DE's competition here
2VSA.F vs GBMB.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, GBMB.F has a market cap of 12.6M. Regarding current trading prices, 2VSA.F is priced at €5.30, while GBMB.F trades at €0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas GBMB.F's P/E ratio is -0.08. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to GBMB.F's ROE of -0.80%. Regarding short-term risk, 2VSA.F is more volatile compared to GBMB.F. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check GBMB.F's competition here
2VSA.F vs CNW.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, CNW.DE has a market cap of 6.5M. Regarding current trading prices, 2VSA.F is priced at €5.30, while CNW.DE trades at €0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas CNW.DE's P/E ratio is -0.44. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to CNW.DE's ROE of -0.49%. Regarding short-term risk, 2VSA.F is less volatile compared to CNW.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check CNW.DE's competition here
2VSA.F vs LD6.F Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, LD6.F has a market cap of 4.3M. Regarding current trading prices, 2VSA.F is priced at €5.30, while LD6.F trades at €0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas LD6.F's P/E ratio is -1.01. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to LD6.F's ROE of -3.29%. Regarding short-term risk, 2VSA.F is less volatile compared to LD6.F. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check LD6.F's competition here
2VSA.F vs MDG1.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, MDG1.DE has a market cap of 2M. Regarding current trading prices, 2VSA.F is priced at €5.30, while MDG1.DE trades at €0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas MDG1.DE's P/E ratio is -0.11. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to MDG1.DE's ROE of -0.58%. Regarding short-term risk, 2VSA.F is less volatile compared to MDG1.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check MDG1.DE's competition here
2VSA.F vs T5O.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, T5O.DE has a market cap of 164.4K. Regarding current trading prices, 2VSA.F is priced at €5.30, while T5O.DE trades at €0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas T5O.DE's P/E ratio is -0.25. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to T5O.DE's ROE of -1.91%. Regarding short-term risk, 2VSA.F is less volatile compared to T5O.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check T5O.DE's competition here
2VSA.F vs AXP.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, AXP.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €5.30, while AXP.DE trades at €153.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas AXP.DE's P/E ratio is 59.63. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to AXP.DE's ROE of +0.05%. Regarding short-term risk, 2VSA.F is more volatile compared to AXP.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check AXP.DE's competition here
2VSA.F vs CNWK.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, CNWK.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €5.30, while CNWK.DE trades at €2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas CNWK.DE's P/E ratio is -5.82. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to CNWK.DE's ROE of -0.86%. Regarding short-term risk, 2VSA.F is more volatile compared to CNWK.DE. This indicates potentially higher risk in terms of short-term price fluctuations for 2VSA.F.Check CNWK.DE's competition here
2VSA.F vs MGNK.DE Comparison August 2025
2VSA.F plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, 2VSA.F stands at 294M. In comparison, MGNK.DE has a market cap of 0. Regarding current trading prices, 2VSA.F is priced at €5.30, while MGNK.DE trades at €0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
2VSA.F currently has a P/E ratio of -1.84, whereas MGNK.DE's P/E ratio is N/A. In terms of profitability, 2VSA.F's ROE is -54.62%, compared to MGNK.DE's ROE of +4.09%. Regarding short-term risk, 2VSA.F is less volatile compared to MGNK.DE. This indicates potentially lower risk in terms of short-term price fluctuations for 2VSA.F.Check MGNK.DE's competition here